Horizon Therapeutics Completes Recruitment for Phase 3 Trial for Treatment of Active Thyroid Eye Disease in Japan


Newswires MT 2022

All news from HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

Analyst Recommendations for HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

2022 sales 3,603 million

2022 net income 531M

Net cash 2022 144M

PER 2022 ratio 33.4x
2022 return
Capitalization 17,235 million
17,235 million
EV / Sales 2022 4.74x
EV / Sales 2023 3.96x
# of employees 2,095
Floating 98.7%

Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY


Duration :

Period :




Horizon Therapeutics Public Limited Company Technical Analysis Chart |  MarketScreener

Technical Analysis Trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

Short term Middle term Long term
Tendencies Bullish Neutral Bearish

Evolution of the income statement

Sale

To buy

Medium consensus TO BUY
Number of analysts 15
Last closing price $76.05
Average target price $104.67
Average Spread / Target 37.6%


Comments are closed.